Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Nova Ltd (NVMI) vs Zoetis Inc (ZTS) Price & Performance

Zoetis IncTrade

Price performance (Past 24H)

Key statistics

Nova Ltd vs Zoetis Inc — how do they compare? Nova Ltd trades at $374.32 (market cap $11.99B), while Zoetis Inc trades at $73.65 (market cap $30.40B). The key difference: Zoetis Inc is far larger — about 2.5× Nova Ltd's market cap, and Zoetis Inc pays a 2.88% dividend while Nova Ltd pays none. Which is the better fit depends on your goals.

NVMIZTS
Market Cap
$11.99B$30.40B
Sector
TechnologyHealth
52-Week High
$605.65$150.61
52-Week Low
$275.78$71.91
Enterprise Value
$11.78B$37.96B
Dividend Yield
2.88%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Nova Ltd

No Aura AI signal available yet.

Zoetis Inc

Zoetis (ZTS) trades at $73.6, down 2.92% on the day, near its 52-week low amid bearish technical signals. The stock shows strong fundamentals with a P/E of 12, net margin of 27.69%, and consistent earnings beats, but faces headwinds from weak U.S. companion animal sales and reduced 2026 guidance. Recent news includes an FDA emergency use authorization for Simparica Trio and participation in healthcare conferences.

The outlook is mixed: valuation appears attractive with a consensus price target of $93.40, but near-term risks include competitive pressures and soft pet health demand. Long-term investors may find value in its profitability and market dominance, though volatility persists from sector challenges and investor sentiment shifts.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Nova Ltd

Nova provides metrology solutions for semiconductor manufacturing. Its systems measure material and process characteristics to help chipmakers control production across advanced nodes and packaging.

Read more on NVMI

About Zoetis Inc

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Read more on ZTS